Byfavo Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(2 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(8 years from now)



Byfavo is a drug owned by Acacia Pharma Ltd. It is used for procedural sedation in adults undergoing short procedures. Byfavo uses Remimazolam Besylate as an active ingredient. Byfavo was launched by Acacia in 2020. It is is available in powder form for intravenous use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 30, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER

More Information on Dosage

BYFAVO family patents

Family Patents